Prime Medicine Inc

Prime Medicine’s CEO and tech leaders exercise 1.3 m stock options, signaling confidence ahead of FDA Fast‑Track HBB trial and potential market‑shifting gene‑editing breakthroughs.

Prime Medicine’s insider buying shows strong confidence in its CRISPR platform—an insider‑driven signal that the company’s gene‑editing pipeline is commercially and scientifically poised for a breakthrough in the biotech market.